Previous 10 | Next 10 |
home / stock / ibrx / ibrx articles
SAN DIEGO, Oct. 09, 2023 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shar...
NEW YORK, Sept. 30, 2023 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ:IBRX) Lifshitz Law PLLC announces investigation into possible securities...
SAN DIEGO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Baxter International, Inc. (NYSE:BAX) Johnson Fistel, LLP is investigating potential claims on be...
Gainers Tenon Medical, Inc. (NASDAQ: TNON) shares climbed 63.5% to $0.2351 after the company announced it has withdrawn its proposed public offer...
U.S. stocks traded lower, with the Dow Jones falling around 90 points on Tuesday. Here are some big stocks recording gains in today’s session...
NEW YORK, Sept. 02, 2023 (GLOBE NEWSWIRE) -- Arrow Financial Corp. (NASDAQ:AROW) Lifshitz Law PLLC announces investigation into possible securi...
SAN FRANCISCO, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges ImmunityBio, Inc. (NASDAQ:IBRX) investors who suffered substantial losses t...
NEW YORK, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in ImmunityBio, Inc. ("ImmunityBio" or the "...
LOS ANGELES, Aug. 28, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-09 10:10:00 ET July 9, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Tech, Biotech, Cleantech and Mining Sectors. The newest tech company is involved in AI and Blo...
2024-07-07 01:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Multiple patients treated across the U.S. with ANKTIVA less than eight weeks after FDA approval of first-in-class cytokine immunotherapy for BCG unresponsive non-muscle invasive bladder cancer ANKTIVA launch initiates the next era of immunotherapy beyond checkpoint inhibitors that is based on...